Digitoxin medication and cancer; case control and internal dose-response studies

BMC Cancer

Table 1 Observed and expected cancer cases among digitoxin users.

ICD-10	Site	Sex	Observed	Expected	SIR (95 % CI)
C50	Breast	F	57	45.7	1.25(0.95, 1.62)
C61	Prostate	M	108	86.7	1.25(1.03, 1.50)
C18–21	Colo-rectal	M+F	127	98.5	1.29(1.06, 1.51)
C32–34	Lung	M+F	63	46.4	1.35(1.04, 1.74)
C64,C65,C67,C68	Kidney, urinary	M+F	59	51.8	1.14(0.87, 1.47)
C43.C44	Melanoma, other skin	M+F	61	49.7	1.23(0.94, 1.58)
C81–C85,C88–C92	Leukemia/Lymphoma	M+F	53	37.5	1.41 (1.06, 1.85)
C00–C97	All sites	M+F	641	502.8	1.27(1.18, 1.37)

Observed and expected cancer cases amoung digitoxin users, and standardized incidence ratio (SIR) presented for all types of cancers having more than 30 expected cases. The cancer types are divided in the groups according to ICD-10 (International Classification of Disease).Observed=cancer cases in the population on digitoxin after start on the drug,no lag time applied. Expected=expected cancer cases calculated by applying the national cancer rates matched exactly on year of birth,age and sex.

ISSN: 1471-2407